88 related articles for article (PubMed ID: 22697346)
21. Tgf-β1 inhibits Cftr biogenesis and prevents functional rescue of ΔF508-Cftr in primary differentiated human bronchial epithelial cells.
Snodgrass SM; Cihil KM; Cornuet PK; Myerburg MM; Swiatecka-Urban A
PLoS One; 2013; 8(5):e63167. PubMed ID: 23671668
[TBL] [Abstract][Full Text] [Related]
22. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules.
Van Goor F; Straley KS; Cao D; González J; Hadida S; Hazlewood A; Joubran J; Knapp T; Makings LR; Miller M; Neuberger T; Olson E; Panchenko V; Rader J; Singh A; Stack JH; Tung R; Grootenhuis PD; Negulescu P
Am J Physiol Lung Cell Mol Physiol; 2006 Jun; 290(6):L1117-30. PubMed ID: 16443646
[TBL] [Abstract][Full Text] [Related]
23. Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect.
Veit G; Oliver K; Apaja PM; Perdomo D; Bidaud-Meynard A; Lin ST; Guo J; Icyuz M; Sorscher EJ; Hartman JL; Lukacs GL
PLoS Biol; 2016 May; 14(5):e1002462. PubMed ID: 27168400
[TBL] [Abstract][Full Text] [Related]
24. Can correcting the ΔF508-CFTR proteostasis-defect rescue CF lung disease?
Valle CW; Vij N
Curr Mol Med; 2012 Aug; 12(7):860-71. PubMed ID: 22697346
[TBL] [Abstract][Full Text] [Related]
25. CFTR: folding, misfolding and correcting the ΔF508 conformational defect.
Lukacs GL; Verkman AS
Trends Mol Med; 2012 Feb; 18(2):81-91. PubMed ID: 22138491
[TBL] [Abstract][Full Text] [Related]
26. Protein processing and inflammatory signaling in Cystic Fibrosis: challenges and therapeutic strategies.
Belcher CN; Vij N
Curr Mol Med; 2010 Feb; 10(1):82-94. PubMed ID: 20205681
[TBL] [Abstract][Full Text] [Related]
27. Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease.
Strub MD; McCray PB
Genes (Basel); 2020 May; 11(5):. PubMed ID: 32414011
[TBL] [Abstract][Full Text] [Related]
28. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
29. Adapting Proteostasis and Autophagy for Controlling the Pathogenesis of Cystic Fibrosis Lung Disease.
Bodas M; Vij N
Front Pharmacol; 2019; 10():20. PubMed ID: 30774592
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological approaches to correcting the ion transport defect in cystic fibrosis.
Roomans GM
Am J Respir Med; 2003; 2(5):413-31. PubMed ID: 14719993
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological treatment of the ion transport defect in cystic fibrosis.
Roomans GM
Expert Opin Investig Drugs; 2001 Jan; 10(1):1-19. PubMed ID: 11116277
[TBL] [Abstract][Full Text] [Related]
32. Novel pharmacological strategies to treat cystic fibrosis.
Hanrahan JW; Sampson HM; Thomas DY
Trends Pharmacol Sci; 2013 Feb; 34(2):119-25. PubMed ID: 23380248
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
